TDS Pharm Co (XKRX:464280) Piotroski F-Score: N/A (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:464280 TDS Pharm Co Ltd XKRX:464280
40 GF Score
Price ₩5,520.00
! 1 Warning Sign
View Full Analysis

What is TDS Pharm Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TDS Pharm Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for TDS Pharm Co's Piotroski F-Score or its related term are showing as below:

During the past 6 years, the highest Piotroski F-Score of TDS Pharm Co was 6. The lowest was 3. And the median was 6.

TDS Pharm Co  (XKRX:464280) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


TDS Pharm Co Piotroski F-Score Related Terms


TDS Pharm Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for TDS Pharm Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TDS Pharm Co Piotroski F-Score Chart

TDS Pharm Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A N/A 6.00 3.00

TDS Pharm Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A 3.00 6.00 N/A

XKRX:464280 vs LLY, JNJ, ABBV: Piotroski F-Score Comparison

For the Drug Manufacturers - General subindustry, TDS Pharm Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TDS Pharm Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TDS Pharm Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where TDS Pharm Co's Piotroski F-Score falls into.


XKRX:464280
40GF Score
TDS Pharm Co Ltd XKRX:464280
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 1460.097 + 1589.069 + 1146.362 + 959.027 = ₩5,155 Mil.
Cash Flow from Operations was 1891.052 + 794.897 + 2293.073 + 1546.025 = ₩6,525 Mil.
Revenue was 8081.97 + 8678.185 + 8067.864 + 8076.564 = ₩32,905 Mil.
Gross Profit was 2548.219 + 2476.92 + 2274.46 + 1907.615 = ₩9,207 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(49986.028 + 51514.684 + 54151.71 + 62007.585 + 63713.381) / 5 = ₩56274.6776 Mil.
Total Assets at the begining of this year (Jun25) was ₩49,986 Mil.
Long-Term Debt & Capital Lease Obligation was ₩37 Mil.
Total Current Assets was ₩37,293 Mil.
Total Current Liabilities was ₩18,670 Mil.
Net Income was 846.691 + 595.774 + 366.355 + 859.011 = ₩2,668 Mil.

Revenue was 6465.271 + 5618.024 + 5277.437 + 5583.281 = ₩22,944 Mil.
Gross Profit was 1888.632 + 1440.23 + 1176.897 + 1301.651 = ₩5,807 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(0 + 50331.32 + 49160.573 + 48538.788 + 49986.028) / 5 = ₩49504.17725 Mil.
Total Assets at the begining of last year (Jun24) was ₩0 Mil.
Long-Term Debt & Capital Lease Obligation was ₩53 Mil.
Total Current Assets was ₩37,482 Mil.
Total Current Liabilities was ₩10,124 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TDS Pharm Co's current Net Income (TTM) was 5,155. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TDS Pharm Co's current Cash Flow from Operations (TTM) was 6,525. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=5154.555/49986.028
=0.10311992

ROA (Last Year)=Net Income/Total Assets (Jun24)
=2667.831/0
=

TDS Pharm Co's return on assets of this year was 0.10311992. TDS Pharm Co's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

TDS Pharm Co's current Net Income (TTM) was 5,155. TDS Pharm Co's current Cash Flow from Operations (TTM) was 6,525. ==> 6,525 > 5,155 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=37.446/56274.6776
=0.00066541

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=53.407/49504.17725
=0.00107884

TDS Pharm Co's gearing of this year was 0.00066541. TDS Pharm Co's gearing of last year was 0.00107884. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=37293.138/18669.758
=1.99751588

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=37482.254/10123.929
=3.70234264

TDS Pharm Co's current ratio of this year was 1.99751588. TDS Pharm Co's current ratio of last year was 3.70234264. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

TDS Pharm Co's number of shares in issue this year was 5.298. TDS Pharm Co's number of shares in issue last year was 5.303. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=9207.214/32904.583
=0.27981555

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=5807.41/22944.013
=0.25311222

TDS Pharm Co's gross margin of this year was 0.27981555. TDS Pharm Co's gross margin of last year was 0.25311222. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=32904.583/49986.028
=0.65827561

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=22944.013/0
=

TDS Pharm Co's asset turnover of this year was 0.65827561. TDS Pharm Co's asset turnover of last year was . ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TDS Pharm Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.


TDS Pharm Co Business Description

Address 253 Pangyo-ro, Pangyo Inno Valley, Building C, Room 403, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.
40GF Score

Get the complete analysis for XKRX:464280

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩5,520.00
Price